Speciality biopharmaceutical company Shire has today joined the ABPI as a full member.
Nicola Massey VP & General Manager of the UK International Speciality Business and Janis Clayton VP & General Manager of the UK Human Genetics Therapy Business, Shire, explain why they decided to join the ABPI:
"Shire is a fast growing company with high ambitions and our UK business continues to evolve; we seek to play a role in the development and growth of our industry so joining the ABPI will be one way of contributing to this. We are looking forward to working with the ABPI and engaging with their wider membership on issues that are important to all of us but most importantly to fight for the needs of our patients."
Nicola Massey will join the ABPI Board of Management with immediate effect.
Stephen Whitehead, Chief Executive of the ABPI, welcomed Shire’s decision:
"I’m delighted Shire has joined the ABPI. This is a critical time for industry and a very important time for our members. The ABPI provides a strong voice and strong leadership for our members and we are very happy to be supporting Shire as we go forward."
Shire is focused on a single purpose: to enable people with life-altering conditions to lead better lives. They focus on chronic symptomatic diseases in areas of unmet needs where the impact of their medicines can make an immediate and tangible difference for patients. This might be a therapy to treat an extremely rare and life-limiting condition such as Hunter syndrome, Gaucher disease, Fabry disease and hereditary angioedema; or a medicine for specialist conditions like ADHD and ulcerative colitis which, if not treated effectively, can dramatically affect the lives of patients and their whole family.
For a list of full ABPI members, visit our full membership list.
ABPI Press OfficeTel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064 Email: firstname.lastname@example.org
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.